Influenza, Human: all 2,265 studies

Page 10 of 23. Open to participants first (174), then studies with results posted, then the rest; newest registration first within each.

• Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) UseCompletedNCT06734741
• Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and OlderCompletedNCT06727058Phase 1/2
• Vaccination Against Influenza Pre-discharge in Heart FailureActive, not recruitingNCT06725927Phase 4
• Maternal Determinants of Immunity to InfluenzaCompletedNCT06716567Phase 4
• Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and OlderCompletedNCT06695130Phase 1/2
• Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and OlderCompletedNCT06695117Phase 1/2
• Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of AgeCompletedNCT06694389Phase 3
• Clinical Evaluation of the VitaSIRO Solo™ Respiratory AssayCompletedNCT06689423
• The Effects of Scapular Taping Techniques on Grip Strength and Hand FunctionCompletedNCT06683196Not applicable
• Study to Assess the Safety and Efficacy of ZX-7101A in Children Aged 5-11 Years With InfluenzaTerminatedNCT06669351Phase 3
• MxA-Guided Antiviral Treatment in Respiratory Viral InfectionsCompletedNCT06668025Not applicable
• Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination RateCompletedNCT06646406Not applicable
• Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral SuspensionCompletedNCT06643156Phase 1
• Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of AgeCompletedNCT06641180Phase 3
• CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and SchoolsActive, not recruitingNCT06640387
• Phase I Clinical Trial of Quadrivalent Influenza Virus Split VaccineActive, not recruitingNCT06622590Phase 1
• Community-based Behavioral Intervention to Increase Vaccination Using MOSTWithdrawnNCT06614361Phase 2
• The Interaction Between Mucosal Microbiota Colonization and the Immune Response to an Intranasal Influenza Live Attenuated VaccineCompletedNCT06609811Phase 4
• Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza ComplicationsCompletedNCT06609460Phase 2
• Vaccine Responses in CancerActive, not recruitingNCT06605625
• Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 SeasonCompletedNCT06603090Not applicable
• Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behavioral Nudges in Increasing InFLUenza Vaccine Uptake Among Adults With Chronic DiseaseCompletedNCT06600490Not applicable
• Influenza Reminder Text-MessagingCompletedNCT06587984Not applicable
• Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836CompletedNCT06582277Phase 2
• Personalized Nudging to Increase Influenza VaccinationsCompletedNCT06566534Not applicable
• Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus LoratadineCompletedNCT06531707Phase 3
• Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery DiseaseCompletedNCT06508437Phase 4
• Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and OlderCompletedNCT06507553Phase 1
• Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical OutcomesCompletedNCT06506812Phase 4
• Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza VaccineWithdrawnNCT06485752Phase 2/3
• To Compare the Safety and PK/ PD Characteristics of ADC189 Between Hepatic Impairment and Normal Hepatic Function SubjectsCompletedNCT06485401Phase 1
• Lot Consistency Study of COVID-19 and Influenza Combination VaccineWithdrawnNCT06482359Phase 2/3
• Single Dose Texas 2017 (H3N2) Challenge StudyCompletedNCT06476275Phase 1
• A Study to Evaluate Safety and Immunogenicity of Haemophilus Influenzae Serotype A VaccineActive, not recruitingNCT06465420Phase 1
• First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LPCompletedNCT06460064Phase 1
• A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol PlusCompletedNCT06385821Phase 3
• A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older AdultsCompletedNCT06382311Phase 1/2
• ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus InfectionCompletedNCT06342921Phase 2/3
• A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.CompletedNCT06342349Phase 1
• Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.CompletedNCT06334510
• Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in RomeCompletedNCT06304038
• Incentives for Influenza VaccinationCompletedNCT06300242Not applicable
• Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza VaccineActive, not recruitingNCT06294262Phase 1/2
• A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination VaccineCompletedNCT06291857Phase 3
• Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated InfluenzaActive, not recruitingNCT06286488Phase 4
• Effectiveness of a Nasal Spray on Viral Respiratory InfectionsCompletedNCT06278324Not applicable
• Effectiveness of Trivalent Influenza Vaccine (TIV) in Type 2 Diabetes Mellitus (T2DM) Patients With and Without Complications of Chronic Kidney Disease (CKD)CompletedNCT06252051Phase 4
• Reducing Respiratory Virus Transmission in Bangladeshi ClassroomsWithdrawnNCT06247059Not applicable
• Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILICompletedNCT06229444Not applicable
• A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast CancerWithdrawnNCT06229392Phase 1
• The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School StudentsActive, not recruitingNCT06208683Phase 4
• Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral InfectionsCompletedNCT06207929
• Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and InfluenzaCompletedNCT06183229Phase 3
• A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic InfluenzaCompletedNCT06179446Phase 1
• A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza.WithdrawnNCT06163677
• Xofluza-Wearables Feasibility-StudyCompletedNCT06161454Phase 4
• Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant FormulaCompletedNCT06158659Not applicable
• HD vs SD Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in GaliciaCompletedNCT06141655Phase 4
• Clinical Evaluation of the Panbio™ COVID-19/Flu A&B PanelCompletedNCT06127108Not applicable
• Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAPCompletedNCT06125717Phase 1
• Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in AdultsCompletedNCT06125691Phase 1
• Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel to Support Home UseCompletedNCT06124638Not applicable
• Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and OlderCompletedNCT06118151Phase 1
• Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza VaccinationCompletedNCT06103994Not applicable
• Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza VaccinesActive, not recruitingNCT06091410Phase 4
• Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Kidney Transplant Recipients -ChronoVAXCompletedNCT06088563Not applicable
• A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of AgeCompletedNCT06087640Phase 3
• Hand Grip Strength in Athletic and Non-Athletic Girls at Different Phases of Menstrual CycleCompletedNCT06086262
• Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES DatabasesCompletedNCT06077045
• Equity Evaluation of Fact Boxes on Informed COVID-19 and Influenza Vaccination Decisions - Study ProtocolCompletedNCT06076421Not applicable
• Motivational Interviewing for Vaccine Uptake in Latinx AdultsTerminatedNCT06062056Not applicable
• Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24CompletedNCT06059456
• Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and Influenza Treatment System With Machine LearningCompletedNCT06052527
• Agaricus Bisporus and Influenza Vaccination ResponseCompletedNCT06041867Not applicable
• Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake Among Adults With Chronic DiseaseCompletedNCT06030739Not applicable
• Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behavioral Nudges in Increasing InFLUenza Vaccine Uptake Among Older AdultsCompletedNCT06030726Not applicable
• Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy AdultsCompletedNCT06028347Phase 1
• The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and OlderCompletedNCT06015282Phase 3
• A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19CompletedNCT05981846Phase 2
• A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy AdultsCompletedNCT05972174Phase 1/2
• Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza VaccinesCompletedNCT05970887Phase 4
• Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy AdultsCompletedNCT05968989Phase 1
• A Study to Evaluate the Effect of a Single Oral Dose of ZX-7101A on the QTc Interval in Healthy SubjectsCompletedNCT05955027Phase 1
• A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy AdultsCompletedNCT05945485Phase 1
• Vaccine Pandemic Preparedness Through Airway Immunology CharacterizationActive, not recruitingNCT05921448Early Phase 1
• Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy ThaisCompletedNCT05895955Phase 1/2
• Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in AdultsCompletedNCT05875961Phase 1
• Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in AdultsCompletedNCT05874713Phase 2
• SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCIActive, not recruitingNCT05869968
• Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza VaccineCompletedNCT05869201Phase 2/3
• COVID-19 Vaccine Uptake Amongst Underserved Populations in East LondonCompletedNCT05866237Not applicable
• Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra®) in Subjects Aged 6 to 35 MonthsCompletedNCT05832333
• Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and AboveCompletedNCT05829356Phase 1
• The Research of Novel Electrolyzed Water Spray to Eradicate Bacteria E-coli and an Attenuated Human Flu VirusCompletedNCT05797103Not applicable
• Comparing the Use of a Mobile App for Surveillance of Adverse Events Following Influenza Immunization to a Web-Based PlatformCompletedNCT05794113Not applicable
• Evaluation of a Flu Vaccination Program Directed at Pregnant Women Assisted at a Research Hospital in Italy.CompletedNCT05785078
• Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 VaccineCompletedNCT05781191
• Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .CompletedNCT05779020Phase 3
• Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge ResponsesCompletedNCT05765955Phase 1
• Combined Molecular Testing for Influenza, SARS-CoV-2, and RSV RNA From Different Upper Airway Specimens.Status unknownNCT05765838Not applicable

← Influenza, Human overview